Treatment of essential thrombocythemia with anagrelide

Murali M. Chintagumpala; Laura L. Kennedy; C. Philip Steuber

doi:10.1016/S0022-3476(95)70090-0

Treatment of essential thrombocythemia with anagrelide

Murali M. Chintagumpala, Laura L. Kennedy, C. Philip Steuber

Houston Methodist

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET. (J PEDIATR 1995; 127:495-8).

Original language	English (US)
Pages (from-to)	495-498
Number of pages	4
Journal	The Journal of Pediatrics
Volume	127
Issue number	3
DOIs	https://doi.org/10.1016/S0022-3476(95)70090-0
State	Published - Sep 1995

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1016/S0022-3476(95)70090-0

Cite this

@article{5ac66bb4b22746ab9f766fb51a14754d,

title = "Treatment of essential thrombocythemia with anagrelide",

abstract = "Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET. (J PEDIATR 1995; 127:495-8).",

author = "Chintagumpala, \{Murali M.\} and Kennedy, \{Laura L.\} and Steuber, \{C. Philip\}",

year = "1995",

month = sep,

doi = "10.1016/S0022-3476(95)70090-0",

language = "English (US)",

volume = "127",

pages = "495--498",

journal = "The Journal of Pediatrics",

issn = "0022-3476",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Treatment of essential thrombocythemia with anagrelide

AU - Chintagumpala, Murali M.

AU - Kennedy, Laura L.

AU - Steuber, C. Philip

PY - 1995/9

Y1 - 1995/9

N2 - Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET. (J PEDIATR 1995; 127:495-8).

AB - Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET. (J PEDIATR 1995; 127:495-8).

UR - https://www.scopus.com/pages/publications/0029164366

UR - https://www.scopus.com/inward/citedby.url?scp=0029164366&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(95)70090-0

DO - 10.1016/S0022-3476(95)70090-0

M3 - Article

C2 - 7658287

AN - SCOPUS:0029164366

SN - 0022-3476

VL - 127

SP - 495

EP - 498

JO - The Journal of Pediatrics

JF - The Journal of Pediatrics

IS - 3

ER -

Treatment of essential thrombocythemia with anagrelide

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this